Founded in 1927, Nordmark is a specialist for the development, manufacturing and commercialization of active pharmaceutical ingredients (APIs) and drug products.
Headquartered in Uetersen near Hamburg, and family owned again after a management buyout from the BASF group in 2001, Nordmark today employs more than 500 employees and generated revenues of around EUR 90 million in 2018.
With 90 years of excellence and commercial success, Nordmark is the ideal partner to bring your ideas to market.
Nordmark Biotech, the biotechnological division of Nordmark, is offering an all-in-one solution for Mammalian Cell Culture, Microbial Fermentation and Microbiome products covering the entire value chain from process development, analytics, production of API and finished drug product up to regulatory affairs and marketing approval.
Our worldwide customers benefit from this integrated approach, which is based on solid project management, long-standing GMP experience and recurrent EMA and FDA approvals.
Collagenase is an enzyme preparation made of Clostridium histolyticum. At Nordmark, collagenase products are manufactured for two different applications: as active ingredients for wound treatment ointments (Collagenase N Powder) and
as biochemicals (Collagenase NB) for use in analytical and medical tissue engineering laboratories. As the World’s largest collagenase manufacturer, Nordmark operates a production plant specifically built for collagenase manufacturing purposes.
We supply pancreatin drug subtances and products in multiple forms and offer a broad range of products with different enzyme activities that can be custom-tailored to your needs. We offer those products in a large variety of tablet shapes and capsule sizes. The active pharmaceutical ingredient pancreatin can be supplied in powder and pellet form.
All our facilities are current Good Manufacturing Practice (cGMP) certified.
Dr. Jan Heyland
Head of Biotech Department
E-mail: Send message